Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 1178
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G49699B5CD9EN
Leaflet:

Download PDF Leaflet

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015’, provides an overview of the Glioblastoma Multiforme (GBM)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Glioblastoma Multiforme (GBM) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Glioblastoma Multiforme (GBM) Overview
Therapeutics Development
Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies
Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes
Glioblastoma Multiforme (GBM) - Pipeline Products Glance
Glioblastoma Multiforme (GBM) - Products under Development by Companies
Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes
Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
Glioblastoma Multiforme (GBM) - Therapeutics Assessment
Drug Profiles
Glioblastoma Multiforme (GBM) - Recent Pipeline Updates
Glioblastoma Multiforme (GBM) - Dormant Projects 1117
Glioblastoma Multiforme (GBM) - Discontinued Products 1128
Glioblastoma Multiforme (GBM) - Product Development Milestones 1131
Appendix 1142

LIST OF FIGURES

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2015
Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

AbbVie Inc.
Actelion Ltd
Actinium Pharmaceuticals, Inc.
Actinogen Limited
Activartis Biotech GmbH
Aduro BioTech, Inc.
Advanced Accelerator Applications SA
Advanced Cancer Therapeutics
Advenchen Laboratories, LLC
Agenus, Inc.
Amal Therapeutics SA
Ambrx, Inc.
Amgen Inc.
Ampio Pharmaceuticals, Inc.
AngioChem Inc.
APIM Therapeutics AS
Apogenix GmbH
Argon Pharma S.L.
Ariad Pharmaceuticals, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Axelar AB
BeiGene(Beijing) Co.,Ltd
Bexion Pharmaceuticals, LLC.
Bioasis Technologies Inc.
BioCancell Ltd
Biomar Microbial Technologies
Bioncotech Therapeutics S.L.
Biovista Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Caladrius Biosciences, Inc.
CalAsia Pharmaceuticals, Inc.
Cavion LLC
Celgene Corporation
Celldex Therapeutics, Inc.
Cellectis S.A.
Celltrion, Inc.
Celsion Corporation
Champions Oncology, Inc.
ChemoCentryx, Inc.
CLL Pharma
CTI BioPharma Corp.
CureFAKtor Pharmaceuticals, LLC
CytomX Therapeutics, Inc.
CytoVac A/S
CytRx Corporation
Deciphera Pharmaceuticals, LLC
DEKK-TEC, Inc.
Delenex Therapeutics AG
Diffusion Pharmaceuticals LLC
DiscoveryBiomed, Inc.
Dr. Reddy's Laboratories Limited
e-Therapeutics Plc
Ecrins Therapeutics SAS
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EnGeneIC Ltd
EntreChem, S.L.
Epirus Biopharmaceuticals, Inc.
ERC Belgium SA
Evotec AG
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
FirstString Research, Inc.
Five Prime Therapeutics, Inc.
Galileo Research s.r.l.
Genentech, Inc.
Genor BioPharma Co., Ltd.
GenSpera, Inc.
Genzyme Corporation
GlaxoSmithKline Plc
GW Pharmaceuticals Plc
HEC Pharm Co., Ltd.
Hospira, Inc.
immatics biotechnologies GmbH
ImmunoCellular Therapeutics, Ltd.
Immunocore Limited
Immunomic Therapeutics, Inc.
Immunovaccine, Inc.
Infinity Pharmaceuticals, Inc.
INSYS Therapeutics, Inc.
InteRNA Technologies B.V.
Intica Biomedical, Inc.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Johnson & Johnson
Kadmon Corporation, LLC
Kalgene Pharmaceuticals Inc.
KaloBios Pharmaceuticals, Inc.
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Komipharm International Co., Ltd.
Lentigen Technology, Inc.
Les Laboratoires Servier SAS
LinXis B.V.
Lixte Biotechnology Holdings, Inc.
Loxo Oncology, Inc.
Mabion SA
Medicenna Therapeutics, Inc
MedImmune, LLC
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Nascent Biotech, Inc.
Nemucore Medical Innovations, Inc.
Nerviano Medical Sciences S.r.l.
Neuralstem, Inc.
NewLink Genetics Corporation
Nexgenix Pharmaceuticals, LLC
Northwest Biotherapeutics, Inc.
Novartis AG
Novogen Limited
Noxxon Pharma AG
Omniox, Inc.
Oncobiologics, Inc.
Oncodesign SA
Oncolytics Biotech Inc.
Onconova Therapeutics, Inc.
Ono Pharmaceutical Co., Ltd.
Orphagen Pharmaceuticals, Inc.
Oryx GmbH & Co. KG
OXiGENE, Inc.
Panacea Biotec Limited
Panacela Labs, Inc.
Peloton Therapeutics, Inc.
Peregrine Pharmaceuticals, Inc.
Pfizer Inc.
PharmAbcine, Inc.
PharmaCyte Biotech, Inc.
Plexxikon Inc.
Prana Biotechnology Limited
Progenics Pharmaceuticals, Inc.
Regulus Therapeutics Inc.
RestorGenex Corporation
Rexahn Pharmaceuticals, Inc.
Rigontec GmbH
Sagetis Biotech, S.L.
Sanofi
Selvita SA
Siena Biotech S.p.A.
Sigma-Tau S.p.A.
Sirnaomics, Inc.
Sorrento Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
STELIS Biopharma Pvt. Ltd.
Stemline Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharmaceutical Industries Limited
Susavion Biosciences, Inc.
Terpenoid Therapeutics, Inc.
Therapeia GmbH & Co. KG
Theravectys SA
Threshold Pharmaceuticals, Inc.
Tocagen Inc.
TRACON Pharmaceuticals, Inc.
TVAX Biomedical, Inc.
Upsher-Smith Laboratories, Inc.
Vascular Biogenics Ltd.
VBI Vaccines Inc.
Vertex Pharmaceuticals Incorporated
ViraTherapeutics GmbH
Virttu Biologics Limited
ZIOPHARM Oncology, Inc.

Global Markets Direct's, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014', provides an overview of the GBM therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for GBM, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for GBM and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

The material was prepared in November, 2014.

LIST OF TABLES

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2015
Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Development by Companies, H2 2015 (Contd..12)
Number of Products under Development by Companies, H2 2015 (Contd..13)
Number of Products under Development by Companies, H2 2015 (Contd..14)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Development by Companies, H2 2015 (Contd..18)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Actelion Ltd, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Actinogen Limited, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Activartis Biotech GmbH, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications SA, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Advanced Cancer Therapeutics, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories, LLC, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Amal Therapeutics SA, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Ambrx, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Argon Pharma S.L., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals, LLC., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Biomar Microbial Technologies, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Bioncotech Therapeutics S.L., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corporation, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Cellectis S.A., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Celltrion, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corporation, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Champions Oncology, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by CLL Pharma, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by CTI BioPharma Corp., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by CureFAKtor Pharmaceuticals, LLC, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by CytomX Therapeutics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by CytoVac A/S, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by CytRx Corporation, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Delenex Therapeutics AG, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals LLC, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by DiscoveryBiomed, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by e-Therapeutics Plc, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by EirGenix Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co., Ltd., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by EntreChem, S.L., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Exelixis, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Five Prime Therapeutics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Galileo Research s.r.l., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Genentech, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co., Ltd., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by GenSpera, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corporation, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by HEC Pharm Co., Ltd., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Hospira, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by immatics biotechnologies GmbH, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Immunocore Limited, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Immunovaccine, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by INSYS Therapeutics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by InteRNA Technologies B.V., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Intica Biomedical, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corporation, LLC, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Kalgene Pharmaceuticals Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co., Ltd., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Lentigen Technology, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by LinXis B.V., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics, Inc, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by MedImmune, LLC, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co., Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Nascent Biotech, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Nemucore Medical Innovations, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Nerviano Medical Sciences S.r.l., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Neuralstem, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corporation, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Nexgenix Pharmaceuticals, LLC, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Novogen Limited, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Omniox, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Oncolytics Biotech Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co. KG, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by OXiGENE, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Panacea Biotec Limited, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Panacela Labs, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Limited, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Progenics Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by RestorGenex Corporation, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Rigontec GmbH, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Sagetis Biotech, S.L., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Selvita SA, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Siena Biotech S.p.A., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau S.p.A., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Sirnaomics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Sun Pharmaceutical Industries Limited, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co. KG, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Theravectys SA, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories, Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc., H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Limited, H2 2015
Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Glioblastoma Multiforme (GBM) Therapeutics - Recent Pipeline Updates, H2 2015
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2015 1151
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H2 2015 1152
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..2), H2 2015 1153
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..3), H2 2015 1154
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..4), H2 2015 1155
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..5), H2 2015 1156
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..6), H2 2015 1157
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..7), H2 2015 1158
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..8), H2 2015 1159
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..9), H2 2015 1160
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..10), H2 2015 1161
Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2015 1162
Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..1), H2 2015 1163
Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..2), H2 2015 1164

Skip to top


Ask Your Question

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: